聚焦加速抗体及新型生物制剂的高浓度制剂开发(英)。Overcoming challenges to formulation development for highly concentrated biologic drug products(≥ 100 mg/mL) requires specialized knowledge and capabilities. The challenge level increases with more complex biologics and with a drive to accelerate development timelines to better serve customer needs.
聚焦加速抗体及新型生物制剂的高浓度制剂开发(英)。Overcoming challenges to formulation development for highly concentrated biologic drug products(≥ 100 mg/mL) requires specialized knowledge and capabilities. The challenge level increases with more complex biologics and with a drive to accelerate development timelines to better serve customer needs.
聚焦加速抗体及新型生物制剂的高浓度制剂开发(英)。Overcoming challenges to formulation development for highly concentrated biologic drug products(≥ 100 mg/mL) requires specialized knowledge and capabilities. The challenge level increases with more complex biologics and with a drive to accelerate development timelines to better serve customer needs.
覆盖 2026 年,全文约 12。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
重点分析了加速抗体及新型生物制剂的高浓度制剂开发(英)等议题。